As self-funding continues to draw the attention of employers and benefits advisors, a number of questions, challenges and opportunities have arisen, leaving many employers and advisors uncertain about how and when to consider making a change.
BenefitsPRO recently caught up with Josh McGee, Vice President of Program Development at Stealth Partner Group, an Amwins Group Company, to discuss the latest trends and strategies when it comes to self-funded plans and specific coverages like gene therapy.
BenefitsPRO: Have there been any trends you've noticed in how self-insured employers have navigated the growing complexities of healthcare coverage like gene therapy?
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
